PinnyPeptide

KPV vs TB-500 Fragment 17-23

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

KPV

Healing & Recovery

Anti-inflammatory tripeptide derived from alpha-melanocyte stimulating hormone.

Peptide B

TB-500 Fragment 17-23

Healing & Recovery

The 7-amino-acid active fragment of TB-500, isolated for cell-migration effects.

Typical vial

5 mg

Typical dose

200-500 mcg

Half-life

~15-30 minutes (short half-life typical of small peptides)

FDA status

Not FDA approved for human use.

Typical vial

10 mg

Typical dose

2000-5000 mcg

Half-life

Estimated minutes to a few hours (much shorter than full TB-500 due to lack of N/C-terminal protection)

FDA status

Not FDA approved for any human or veterinary use. No clinica…

KPV effects

  • Potent anti-inflammatory action via NF-kB inhibition
  • Reduces intestinal inflammation when taken orally
  • Exhibits antimicrobial activity against bacteria and fungi
  • Modulates pro-inflammatory cytokine release
  • Supports gut barrier integrity

TB-500 Fragment 17-23 effects

  • Binds G-actin and modulates actin polymerization
  • In vitro promotion of keratinocyte and endothelial cell migration
  • Pro-angiogenic activity in cell-based assays
  • Pro-healing effects on cultured fibroblasts
  • Anti-inflammatory effects (limited to in vitro evidence)
  • Potentially shared but reduced systemic activity vs full TB-500

KPV side effects

  • Generally well tolerated at studied doses
  • Mild gastrointestinal discomfort at higher doses
  • Temporary skin flushing (rare)

TB-500 Fragment 17-23 side effects

  • Injection site irritation or redness
  • Lethargy (anecdotal, mechanism unclear)
  • Mild flu-like symptoms at higher doses (rare)
  • Headache
  • Unknown long-term effects — no human safety data

KPV dosing ranges

Gut inflammation support

200-500 mcg · Once or twice daily (oral or SubQ) · 4-8 weeks

Systemic anti-inflammatory

200-500 mcg · Once daily (SubQ) · 4-6 weeks

TB-500 Fragment 17-23 dosing ranges

Injury recovery (extrapolated)

2-5 mg · Twice weekly SubQ · 4-6 weeks

Tendon/ligament support (extrapolated)

2-5 mg · Twice weekly SubQ · 4-8 weeks

Loading phase (anecdotal)

5 mg · Twice weekly for 2-3 weeks · Then maintenance

KPV vs TB-500 Fragment 17-23 — common questions

What is the difference between KPV and TB-500 Fragment 17-23?

KPV: Anti-inflammatory tripeptide derived from alpha-melanocyte stimulating hormone. Typical dose 200-500 mcg. TB-500 Fragment 17-23: The 7-amino-acid active fragment of TB-500, isolated for cell-migration effects. Typical dose 2000-5000 mcg. Both fall under the Healing & Recovery category.

Can you stack KPV and TB-500 Fragment 17-23?

Stacking KPV with TB-500 Fragment 17-23 is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, KPV or TB-500 Fragment 17-23?

KPV is typically dosed: Once or twice daily (oral or SubQ) for Gut inflammation support; Once daily (SubQ) for Systemic anti-inflammatory. TB-500 Fragment 17-23 is typically dosed: Twice weekly SubQ for Injury recovery (extrapolated); Twice weekly SubQ for Tendon/ligament support (extrapolated); Twice weekly for 2-3 weeks for Loading phase (anecdotal).

Are KPV and TB-500 Fragment 17-23 FDA approved?

KPV: Not FDA approved for human use. TB-500 Fragment 17-23: Not FDA approved for any human or veterinary use. No clinical trials have been conducted on this specific fragment.

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free